Source comparison
Tesamorelin + Ipamorelin: Research Model Comparison
GHRH Receptor Density 35–40% higher per somatotroph Baseline human reference Rodents bind synthetic GHRH analogues more readily Dose scaling from animal data systematically overestimates human receptor occupancy Peak GH Response (2mg tesamorelin) 18–24ng/mL at
This comparison does not assign a generated winner or score.
- GHRH Receptor Density
- 35–40% higher per somatotroph
- Baseline human reference
- Rodents bind synthetic GHRH analogues more readily
- Dose scaling from animal data systematically overestimates human receptor occupancy
- Peak GH Response (2mg tesamorelin)
- 18–24ng/mL at 30 min
- 8–14ng/mL at 30 min
- ~50% lower human response at equivalent mg/kg dose
- Human dose-response plateaus earlier. Doubling dose yields <15% additional GH
- Ipamorelin Dose Ceiling
- Linear response up to 500mcg/kg
- Plateau at 100–150mcg total
- Rodents tolerate higher per-weight dosing
- Human trials show diminishing returns above 100mcg. Receptor saturation limits
- Synergy Magnitude
- Supra-additive (600–700% baseline)
- Additive (440% baseline)
- 25–35% lower combined effect in humans
- Convergent signaling pathways amplify less in human somatotrophs
- GH Elevation Duration
- 90–120 minutes sustained
- 30–45 min peak, baseline by 90 min
- Shorter human exposure window
- Reduced duration affects IGF-1 conversion. Human trials show 4–5h elevation vs 6–8h in rodents
- Adverse Event Profile
- Minimal GI disturbance
- Injection-site reactions, transient hyperglycemia
- Human trials report 12–18% mild AE rate
- Animal models underpredict human tolerability issues at higher doses